Published in Obesity and Diabetes Week, October 27th, 2008
"The efficacy analysis was based on the all-patients-treated population using an analysis of co-variance with change in HbA(1c) from baseline as the primary endpoint. The mean baseline HbA(1c) was 7.7% for...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week